Fennec Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025
Fennec Pharmaceuticals (NASDAQ: FENC; TSX: FRX) has scheduled the release of its first quarter 2025 financial results for Tuesday, May 13, 2025, before U.S. markets open. The company will host a conference call and webcast at 8:30 a.m. ET on the same day to discuss their financial and business results.
Interested parties can access the webcast through the company's website at www.fennecpharma.com under the Investors & Media section. Participants are advised to connect at least 15 minutes before the call to allow time for any necessary software downloads. A replay of the webcast will be available on the company's website for 30 days following the event.
Fennec Pharmaceuticals (NASDAQ: FENC; TSX: FRX) ha programmato la pubblicazione dei risultati finanziari del primo trimestre 2025 per martedì 13 maggio 2025, prima dell'apertura dei mercati statunitensi. La società terrà una conference call e una webcast alle 8:30 a.m. ET dello stesso giorno per discutere i risultati finanziari e aziendali.
Gli interessati potranno seguire la webcast tramite il sito web dell'azienda all'indirizzo www.fennecpharma.com nella sezione Investors & Media. Si consiglia ai partecipanti di collegarsi almeno 15 minuti prima della chiamata per consentire eventuali download di software necessari. La registrazione della webcast sarà disponibile sul sito web della società per 30 giorni dopo l'evento.
Fennec Pharmaceuticals (NASDAQ: FENC; TSX: FRX) ha programado la publicación de sus resultados financieros del primer trimestre de 2025 para el martes 13 de mayo de 2025, antes de la apertura de los mercados estadounidenses. La compañía realizará una llamada en conferencia y una transmisión en vivo a las 8:30 a.m. ET del mismo día para discutir sus resultados financieros y comerciales.
Los interesados pueden acceder a la transmisión en vivo a través del sitio web de la empresa en www.fennecpharma.com, en la sección Investors & Media. Se recomienda a los participantes conectarse al menos 15 minutos antes de la llamada para permitir cualquier descarga de software necesaria. La repetición de la transmisión estará disponible en el sitio web de la empresa durante 30 días después del evento.
Fennec Pharmaceuticals (NASDAQ: FENC; TSX: FRX)는 2025년 5월 13일 화요일 미국 시장 개장 전에 2025년 1분기 재무 실적을 발표할 예정입니다. 회사는 같은 날 동부 시간 기준 오전 8시 30분에 재무 및 사업 실적에 대해 논의하는 컨퍼런스 콜과 웹캐스트를 진행할 예정입니다.
관심 있는 분들은 회사 웹사이트 www.fennecpharma.com의 Investors & Media 섹션을 통해 웹캐스트에 접속할 수 있습니다. 참가자는 필요한 소프트웨어 다운로드를 위해 최소 15분 전에 접속할 것을 권장합니다. 웹캐스트 녹화는 행사 후 30일 동안 회사 웹사이트에서 다시 볼 수 있습니다.
Fennec Pharmaceuticals (NASDAQ : FENC ; TSX : FRX) a prévu la publication de ses résultats financiers du premier trimestre 2025 pour le mardi 13 mai 2025, avant l'ouverture des marchés américains. La société organisera une conférence téléphonique et une webdiffusion à 8h30, heure de l'Est le même jour pour discuter de ses résultats financiers et commerciaux.
Les personnes intéressées peuvent accéder à la webdiffusion via le site internet de la société à l'adresse www.fennecpharma.com dans la section Investors & Media. Il est conseillé aux participants de se connecter au moins 15 minutes avant l'appel afin de permettre le téléchargement éventuel de logiciels nécessaires. La rediffusion de la webdiffusion sera disponible sur le site de la société pendant 30 jours après l'événement.
Fennec Pharmaceuticals (NASDAQ: FENC; TSX: FRX) hat die Veröffentlichung der Finanzergebnisse für das erste Quartal 2025 für Dienstag, den 13. Mai 2025, vor Öffnung der US-Märkte geplant. Das Unternehmen wird am selben Tag um 8:30 Uhr ET eine Telefonkonferenz und einen Webcast abhalten, um die finanziellen und geschäftlichen Ergebnisse zu besprechen.
Interessierte können über die Website des Unternehmens unter www.fennecpharma.com im Bereich Investors & Media auf den Webcast zugreifen. Teilnehmer werden gebeten, sich mindestens 15 Minuten vor Beginn der Telefonkonferenz einzuwählen, um eventuelle Software-Downloads zu ermöglichen. Eine Aufzeichnung des Webcasts wird für 30 Tage nach der Veranstaltung auf der Website verfügbar sein.
- None.
- None.
RESEARCH TRIANGLE PARK, N.C., May 08, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its first quarter 2025 financial results before the opening of the U.S. financial markets on Tuesday, May 13, 2025. Management will host a conference call and webcast that day to discuss the Company’s financial and business results.
Conference Call & Webcast Detail:
| Date: | Tuesday, May 13, 2025 |
| Time: | 8:30 a.m. ET |
| Webcast Link: | https://edge.media-server.com/mmc/p/nb5vbq6o |
| Participant Link: | https://register-conf.media-server.com/register/BIbc2eaa3f157d4c6891b71246a83bdb02 |
To access the live webcast link, log onto www.fennecpharma.com and proceed to the News & Events/Event Calendar page under the Investors & Media heading. Please connect to the company’s website at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to listen to the webcast. A webcast replay of the conference call will also be archived on www.fennecpharma.com for thirty days.
About Fennec Pharmaceuticals
Fennec Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development and commercialization of PEDMARK to reduce the risk of platinum-induced ototoxicity in pediatric patients. Further, PEDMARK received FDA approval in September 2022 and European Commission approval in June 2023 and U.K. approval in October 2023 under the brand name PEDMARQSI. PEDMARK has received Orphan Drug Exclusivity in the U.S. and PEDMARQSI has received Pediatric Use Marketing Authorization in Europe, which includes eight years plus two years of data and market protection. For more information, please visit www.fennecpharma.com.
For further information, please contact:
Investors:
Robert Andrade
Chief Financial Officer
Fennec Pharmaceuticals Inc.
+1 919-246-5299
Corporate and Media:
Lindsay Rocco
Elixir Health Public Relations
+1 862-596-1304
lrocco@elixirhealthpr.com
FAQ
When will Fennec Pharmaceuticals (FENC) release Q1 2025 earnings?
What time is Fennec Pharmaceuticals' Q1 2025 earnings call?
How can I access Fennec Pharmaceuticals' Q1 2025 earnings webcast?
How long will Fennec Pharmaceuticals' Q1 2025 earnings webcast replay be available?
